Area of research
Infectious Diseases · Virology
Research interest
Research interests include HIV Research and Treatment, SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, and Immune Cell Function and Interaction.
Pediatric long COVID is characterized by myeloid CCR6 suppression and immune dysregulation
Optimized ACE2-Fc fusion proteins with picomolar neutralization activity against highly evolved SARS-CoV-2 variants.
Better and closer glycan-independent anti-V3 antibodies to help HIV-1 vaccine.
Multiple roles of humoral responses in the control of HIV infection.
TARDBP as a regulator of HIV-1 assembly and infection: a review of targeting the viral capsid precursor Pr55Gag and limiting viral core entry.
Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections.
Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood.
Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m<sup>6</sup>A protein synthesis routes.
A human-ACE2 knock-in mouse model for SARS-CoV-2 infection recapitulates respiratory disorders but avoids neurological disease associated with the transgenic K18-hACE2 model.
Initial antigen encounter determines robust T-cell immunity against SARS-CoV-2 BA.2.86 variant three years later
Recurrent waning of anti-SARS-CoV-2 neutralizing antibodies despite multiple antigen encounters.
Long-lasting antibody B-cell responses to SARS-CoV-2 three years after the onset of the pandemic.
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.
Tracking the soluble biomarkers of MIS-C and their association with clinical parameters and severity.
TARDBP as a Gatekeeper of HIV-1 Assembly and Infection: Targeting the Viral Capsid Precursor Pr55Gag and Limiting Viral Core Entry
Rethinking Optimal Immunogens to Face SARS-CoV-2 Evolution Through Vaccination.
Comparison of Three Commercial ELISA Kits for Detection of Antibodies Against SARS-CoV-2 in Serum Samples from Different Animal Species.
Patient and donor antibody profiles in early COVID-19 convalescent plasma therapy in the COnV-ert trial.
Determinants of antibody levels and protection against omicron BQ.1/XBB breakthrough infection.
Under the Radar: Immune Evasion, Pathogenesis and Control of HIV Infection.
Isolation and structure elucidation of Dm-CVNH, a new cyanovirin-N homolog with activity against SARS-CoV-2 and HIV-1.
Anti-SARS-CoV-2 antibodies from severe COVID-19 individuals or S2 immunizations do not worsen disease in hamsters.
Immune Durability and Breakthrough Infections 15 Months After SARS-CoV-2 Boosters in People over 65: The IMMERSION Study.
Immunogenicity and Safety of PHH-1V COVID-19 Vaccine as a Heterologous Booster in Adolescents
A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity.
VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
Production and characterization of novel Anti-HIV Fc-fusion proteins in plant-based systems: Nicotiana benthamiana & tobacco BY-2 cell suspension.
Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
NSGS mice humanized with cord blood mononuclear cells show sustained and functional myeloid-lymphoid representation with limited graft-versus-host disease.
Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention.